New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis

Rheumatoid Arthritis

AMCP Science & Innovation Theater Webinar


  • James T. Kenney, MBA, RPh, President, JTKENNEY, LLC
  • Alif Saleh, CEO, Scipher Medicine

Drug costs for targeted autoimmune diseases account for a large and growing proportion of pharmacy spend per patient. Despite most rheumatoid arthritis patients receiving anti-TNF therapies as their first targeted treatment, 2 in 3 patients have an inadequate response to these drugs. Even after patients fail treatment, many still cycle through multiple anti-TNF therapies before trying something different. The resulting healthcare waste is enormous: with annual sales of $33 billion, anti-TNF therapies are the world’s largest selling drug class.

PrismRA® from Scipher Medicine is a groundbreaking molecular signature test now available at the request of commercial payers and rheumatologists seeking relief from this pain point in reimbursement and prescribing. PrismRA® identifies patients who are unlikely to have an adequate response to anti-TNF therapies with 90% accuracy. Once stratified, clinicians can initiate an alternative mechanism of action, increasing the number of patients who respond to initial RA therapy by 40%.